CCR5 blockade for neuroinflammatory diseases — beyond control of HIV

High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc

(2015) Lidia Stork et al.   ACTA NEUROPATHOLOGICA

Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8+ T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome

(2015) Guillaume Martin-Blondel et al.   ACTA NEUROPATHOLOGICA

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes

(2015) Josep M. Llibre et al.   ANTIVIRAL RESEARCH

The maraviroc expanded access program — safety and efficacy data from an open-label study

(2015) Adriano Lazzarin et al.   HIV CLINICAL TRIALS

Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch

(2015) JM Tiraboschi et al.   HIV MEDICINE

Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers

(2015) Wendy E. Walker et al.   JOURNAL OF VIROLOGY

Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity

(2014) Jason W. Griffith et al.   Annual Review of Immunology

From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development

(2014) Avraham Ben-Nun et al.   JOURNAL OF AUTOIMMUNITY

CCR5 Expression Levels Influence NFAT Translocation, IL-2 Production, and Subsequent Signaling Events during T Lymphocyte Activation

(2014) J. F. Camargo et al.   JOURNAL OF IMMUNOLOGY

CCR5 Knockout Prevents Neuronal Injury and Behavioral Impairment Induced in a Transgenic Mouse Model by a CXCR4-Using HIV-1 Glycoprotein 120

(2014) Ricky Maung et al.   JOURNAL OF IMMUNOLOGY

Maraviroc Reduces the Regulatory T-Cell Frequency in Antiretroviral-Naive HIV-Infected Subjects

(2014) María Mar Pozo-Balado et al.   JOURNAL OF INFECTIOUS DISEASES

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)

(2014) Lishomwa C. Ndhlovu et al.   JOURNAL OF NEUROVIROLOGY

Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances

(2014) Sophia Varadkar et al.   LANCET NEUROLOGY

Maraviroc and JC Virus–Associated Immune Reconstitution Inflammatory Syndrome

(2014) Paul S. Giacomini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Subversion by Mycobacterium tuberculosis through CCR5 Mediated Signaling: Involvement of IL-10

(2014) Shibali Das et al.   PLoS One

Polymorphisms in Chemokine Receptor 5 and Toll-Like Receptor 3 Genes Are Risk Factors for Clinical Tick-Borne Encephalitis in the Lithuanian Population

(2014) Auksė Mickienė et al.   PLoS One

Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial

(2014) Juan G Sierra-Madero et al.   Lancet HIV

Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies

(2014) Béatrice SL Pignolet et al.   OncoImmunology

The chemokine receptorCCR5 Δ32allele in natalizumab-treated multiple sclerosis

(2013) M. Møller et al.   ACTA NEUROLOGICA SCANDINAVICA

Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques

(2013) Kathleen M. Kelly et al.   AIDS

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

(2013) Matteo Vassallo et al.   AIDS

Association of single nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with predisposition to tick-borne encephalitis in a Russian population

(2013) Andrey V. Barkhash et al.   ANTIVIRAL RESEARCH

Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia

(2013) Nicoletta Ciccarelli et al.   ANTIVIRAL THERAPY

Randomized Trial of Central Nervous System–Targeted Antiretrovirals for HIV-Associated Neurocognitive Disorder

(2013) Ronald J. Ellis et al.   CLINICAL INFECTIOUS DISEASES

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients

(2013) Roy M. Gulick et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV-associated neurocognitive disorder

(2013) David B Clifford et al.   LANCET INFECTIOUS DISEASES

In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection

(2013) G. Martin-Blondel et al.   NEUROLOGY

Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex

(2013) Q. Tan et al.   SCIENCE

HIV-1 entry inhibitors: recent development and clinical use

(2013) Timothy J Henrich et al.   Current Opinion in Virology

Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration

(2012) David Croteau et al.   AIDS

Progressive Multifocal Leukoencephalopathy: Why Gray and White Matter

(2012) Sarah Gheuens et al.   Annual Review of Pathology-Mechanisms of Disease

Effect of Maraviroc on HIV Disease Progression-Related Biomarkers

(2012) M. Concepción Romero-Sánchez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis

(2012) C. G. Bien et al.   BRAIN

CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1/M2 Status

(2012) H. Kitade et al.   DIABETES

Rasmussen encephalitis: Incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins

(2012) Christian G. Bien et al.   EPILEPSIA

Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration

(2012) Lise Cuzin et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

(2012) Alexia Cusini et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

In vitro effects of the CCR5 inhibitor maraviroc on human T cell function

(2012) H. Arberas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Indispensable Role of CCR5 for In Vivo Suppressor Function of Tumor-Derived CD103+ Effector/Memory Regulatory T Cells

(2012) L.-Y. Chang et al.   JOURNAL OF IMMUNOLOGY

CCR2+CCR5+ T Cells Produce Matrix Metalloproteinase-9 and Osteopontin in the Pathogenesis of Multiple Sclerosis

(2012) W. Sato et al.   JOURNAL OF IMMUNOLOGY

Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration

(2012) Dong-Young Choi et al.   NEUROBIOLOGY OF DISEASE

Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management?

(2012) C. Antoniol et al.   NEUROLOGY

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

(2012) Ran Reshef et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Chemokine Receptor CCR5, a Therapeutic Target for HIV/AIDS Antagonists, Is Critical for Recovery in a Mouse Model of Japanese Encephalitis

(2012) Maximilian Larena et al.   PLoS One

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

(2012) Dona L Fleishaker et al.   ARTHRITIS RESEARCH & THERAPY

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy

(2011) Imke Metz et al.   ACTA NEUROPATHOLOGICA

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research

(2011) Lucette A Cysique et al.   BMC Neurology

Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV

(2011) G. Martin-Blondel et al.   BRAIN

In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells

(2011) R. Rossi et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The Relationship of CCR5 Antagonists to CD4+ T-Cell Gain: A Meta-Regression of Recent Clinical Trials in Treatment-Experienced HIV-Infected Patients

(2011) Timothy J. Wilkin et al.   HIV CLINICAL TRIALS

Mimic peptides bonding specifically with the first and second extracellular loops of the CC chemokine receptor 5 derived from a phage display peptide library are potent inhibitors of experimental autoimmune encephalomyelitis

(2011) Hui-min Zheng et al.   INFLAMMATION RESEARCH

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

(2011) L. Garvey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Chemokines control naive CD8+T cell selection of optimal lymph node antigen presenting cells

(2011) Heather D. Hickman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Inflammatory chemokine receptors regulate CD8+T cell contraction and memory generation following infection

(2011) Jacob E. Kohlmeier et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Regional and mucosal memory T cells

(2011) Brian S Sheridan et al.   NATURE IMMUNOLOGY

Immune reconstitution inflammatory syndrome in natalizumab-associated PML

(2011) I. L. Tan et al.   NEUROLOGY

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

(2011) P. Vermersch et al.   NEUROLOGY

In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection

(2011) Pasqua Gramegna et al.   PLoS One

Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

(2011) Carolina Gutiérrez et al.   PLoS One

Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms

(2010) Giovanna Melica et al.   AIDS

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

(2010) Ana Canestri et al.   CLINICAL INFECTIOUS DISEASES

Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients

(2010) Juan Manuel Tiraboschi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc

(2010) Raffaella Rossi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Fusion Protein Encoding the Second Extracellular Domain of CCR5 Arrests Chemokine-Induced Cosignaling and Effectively Suppresses Ongoing Experimental Autoimmune Encephalomyelitis

(2010) Y. Sapir et al.   JOURNAL OF IMMUNOLOGY

CD8 T Cells Activated in Distinct Lymphoid Organs Differentially Express Adhesion Proteins and Coexpress Multiple Chemokine Receptors

(2010) A. R. Ferguson et al.   JOURNAL OF IMMUNOLOGY

Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis

(2010) Monika Müller et al.   LANCET INFECTIOUS DISEASES

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell–licensed DCs

(2010) Verena Semmling et al.   NATURE IMMUNOLOGY

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients

(2010) Nicholas Funderburg et al.   PLoS One

The chemokine receptor CCR5 in the central nervous system

(2010) Silvia Sorce et al.   PROGRESS IN NEUROBIOLOGY

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients

(2009) Aylin Yilmaz et al.   AIDS

Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?

(2009) Guillaume Martin-Blondel et al.   AIDS

CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery

(2009) Nicholas Schwab et al.   BRAIN

The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function

(2009) Jia Ni et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3- and 6-glucuronide in the human brain*

(2009) Derek J. Roberts et al.   CRITICAL CARE MEDICINE

Chemokines released from astrocytes promote chemokine receptor 5-mediated neuronal cell differentiation

(2009) Mi Hee Park et al.   EXPERIMENTAL CELL RESEARCH

CCR5 Deficiency Is a Risk Factor for Early Clinical Manifestations of West Nile Virus Infection but not for Viral Transmission

(2009) Jean K. Lim et al.   JOURNAL OF INFECTIOUS DISEASES

Expression of Chemokines and Their Receptors by Human Brain Endothelium: Implications for Multiple Sclerosis

(2009) Eve A. Subileau et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

PML-IRIS in patients with HIV infection: Clinical manifestations and treatment with steroids

(2009) K. Tan et al.   NEUROLOGY

Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System

(2008) Scott Letendre   ARCHIVES OF NEUROLOGY

The Chemokine Receptor CCR5 Plays a Key Role in the Early Memory CD8+ T Cell Response to Respiratory Virus Infections

(2008) Jacob E. Kohlmeier et al.   IMMUNITY

Case of Yellow Fever Vaccine–Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES Genes

(2008) Bali Pulendran et al.   JOURNAL OF INFECTIOUS DISEASES

A Deletion in the Chemokine Receptor 5(CCR5)Gene Is Associated with Tickborne Encephalitis

(2008) Elin Kindberg et al.   JOURNAL OF INFECTIOUS DISEASES

Genetic Deficiency of Chemokine Receptor CCR5 Is a Strong Risk Factor for Symptomatic West Nile Virus Infection: A Meta‐Analysis of 4 Cohorts in the US Epidemic

(2008) Jean K. Lim et al.   JOURNAL OF INFECTIOUS DISEASES

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

(2008) Roy M. Gulick et al.   NEW ENGLAND JOURNAL OF MEDICINE

CXCR4-CCR5: A couple modulating T cell functions

(2008) R. L. Contento et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT)

(2008) D. K. Walker et al.   XENOBIOTICA